TY - JOUR
T1 - CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
AU - Esteva, Francisco J.
AU - Wang, Jing
AU - Lin, Feng
AU - Mejia, Jaime A.
AU - Yan, Kai
AU - Altundag, Kadri
AU - Valero, Vicente
AU - Buzdar, Aman U.
AU - Hortobagyi, Gabriel N.
AU - Symmans, W. Fraser
AU - Pusztai, Lajos
N1 - Publisher Copyright:
© 2007 Esteva et al.
PY - 2007/12/17
Y1 - 2007/12/17
N2 - Introduction: We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC). Methods: Pretreatment fine-needle aspiration specimens from 45 patients with HER-2-overexpressing stage II to IIIA breast cancer were subjected to transcriptional profiling and examined for differential expression of various genes and gene sets. The primary endpoint for tumor response was pathologic complete response (pCR). Correlations between pCR and gene expression were sought. Results: The overall pCR rate was 64%. Age, nuclear grade, tumor size, nodal status, quantitative expression of estrogen and HER-2 receptor mRNA, and HER-2 gene copy number showed no correlation with pCR. Results of gene set enrichment analysis suggested that the lower expression of genes involved with CD40 signaling is associated with a greater risk of residual cancer after the preoperative chemotherapy that includes trastuzumab. Conclusion: CD40 signaling may play a role in determining response to trastuzumab-plus-T/FEC therapy in patients with HER-2-overexpressing breast cancer.
AB - Introduction: We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC). Methods: Pretreatment fine-needle aspiration specimens from 45 patients with HER-2-overexpressing stage II to IIIA breast cancer were subjected to transcriptional profiling and examined for differential expression of various genes and gene sets. The primary endpoint for tumor response was pathologic complete response (pCR). Correlations between pCR and gene expression were sought. Results: The overall pCR rate was 64%. Age, nuclear grade, tumor size, nodal status, quantitative expression of estrogen and HER-2 receptor mRNA, and HER-2 gene copy number showed no correlation with pCR. Results of gene set enrichment analysis suggested that the lower expression of genes involved with CD40 signaling is associated with a greater risk of residual cancer after the preoperative chemotherapy that includes trastuzumab. Conclusion: CD40 signaling may play a role in determining response to trastuzumab-plus-T/FEC therapy in patients with HER-2-overexpressing breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=40349089816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40349089816&partnerID=8YFLogxK
U2 - 10.1186/bcr1836
DO - 10.1186/bcr1836
M3 - Article
C2 - 18086299
AN - SCOPUS:40349089816
SN - 1465-5411
VL - 9
JO - Breast Cancer Research
JF - Breast Cancer Research
IS - 6
M1 - R87
ER -